Avacta Group (LSE:AVCT) will present two posters at the ESMO 2026 Congress in Madrid. One will include progression-free survival data for its lead candidate AVA6000 in salivary gland cancers. The other will describe the trial design for its second clinical candidate, AVA6103. The announcement does not include any of the data values.
What was announced
On 14 October 2026, Avacta Group said it will present two posters at the European Society for Medical Oncology (ESMO) 2026 Congress, which runs in Madrid from 23 to 27 October 2026.
The first, poster 1549P, covers the Phase 1a/1b trial of FAP-Dox (AVA6000) in salivary gland cancers. It is scheduled for Monday 26 October, from 12:00 to 12:45 CET. Avacta said the poster will include progression-free survival (PFS) data from patients with salivary gland cancer and FAPI-PET imaging data from the trial's expansion cohort.
The second, poster 1134eTiP, will appear in the e-Poster Trial in Progress session. It sets out the design of the Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) and includes updated preclinical data.
The release does not give any PFS values, patient numbers, response rates or safety data, and it contains no comments from executives. The substance of the data will only be known when the posters are presented.
The two candidates
AVA6000 is a peptide drug conjugate that delivers the established chemotherapy drug doxorubicin. It is designed so that the drug is released by fibroblast activation protein (FAP), an enzyme found at high levels in the tumour microenvironment. The aim of this approach is to concentrate the chemotherapy's activity in tumour tissue and limit exposure in healthy tissue.
AVA6103 is Avacta's second clinical candidate. It is the first to use the company's next-generation pre|CISION controlled-release mechanism. Avacta said it is aimed at tumours that are sensitive to exatecan, a topoisomerase I inhibitor class of chemotherapy. As with AVA6000, the design is meant to release the active drug mainly where FAP is present, so that less of it reaches healthy tissue. The FOCUS-01 poster describes how the Phase 1 trial is set up, not results from it.
Why the data matters
Progression-free survival measures how long patients live without their disease getting worse. It is a widely used efficacy measure in cancer trials, particularly where tumours grow slowly or few treatments are available. Salivary gland cancers are rare, and doctors have limited options for patients with advanced disease. Avacta is studying AVA6000 in this group as part of its Phase 1 programme.
FAPI-PET imaging uses a radiolabelled tracer that binds to FAP, so scans can show how much of the target enzyme is present in a patient's tumours. Imaging data from the expansion cohort could help show whether patients' tumours express FAP, which is the basis of the AVA6000 mechanism. Avacta has not said what the imaging shows.
Because this is an early-phase study, any PFS data will come from a relatively small, uncontrolled patient group. Readers will need to judge results in that context, and in particular how many patients are included and how long they have been followed up. The release does not provide these details.
What to watch next
The main event is the presentation of poster 1549P on 26 October. The PFS figures, patient numbers and FAPI-PET findings in it will be the first detailed look at how AVA6000 has performed in salivary gland cancers. The FOCUS-01 trial-in-progress poster should give more detail on how AVA6103 is being tested in the clinic. Avacta (LSE:AVCT) may publish the posters or comment on the data around the congress, but the announcement does not say whether it will.






Please wait processing your request...